Good
Mostly Aligned
Patient Risk:
Low
Summary
Generally aligned with the label: multiple accurate statements about guaifenesin, DXM-containing products, and MAOI interactions are supported by the label. Several antidepressant-interaction claims are not explicitly stated in the label or extend beyond its content, and dosing details are not captured in the claims.
Category Scores
Accurate Statements
Guaifenesin works as an expectorant to thin mucus.
Indications and Usage; Directions
Plain Mucinex contains guaifenesin only.
Indications and Usage; Active Ingredients
Mucinex DM contains guaifenesin + dextromethorphan.
Active Ingredients; Indications and Usage
Mucinex with pseudoephedrine contains guaifenesin + decongestant.
Active Ingredients; Indications and Usage
Dextromethorphan (DXM) can interact with SSRIs, SNRIs, and MAOIs.
Warnings; Drug Interactions
Dextromethorphan can raise the risk of serotonin syndrome when taken with antidepressants.
Warnings; Drug Interactions
Symptoms of serotonin syndrome include agitation, rapid heart rate, fever, and seizures.
Warnings; Drug Interactions
The FDA labels for Mucinex warn against use with MAOIs within 14 days.
Warnings; Drug Interactions
MAOIs (e.g., Nardil, Parnate): Highest risk—even plain Mucinex with pseudoephedrine can cause hypertensive crisis.
Warnings; Drug Interactions
Ask before combining if you have conditions like high blood pressure, glaucoma, or take multiple meds.
Warnings; Drug Interactions
Symptoms of interaction? Stop use and seek help.
Warnings; Directions
Unsupported Statements
Mucinex (guaifenesin) generally does not interact with most antidepressants.
Label does not explicitly state a general antidepressant interaction profile; it discusses DXM interactions and MAOI considerations.
Guaifenesin does not affect brain chemicals targeted by antidepressants.
Label provides no information about brain chemicals or antidepressant targets.
Avoid Mucinex DM, Maximum Strength, or Fast-Maxx products containing dextromethorphan (DXM).
Label warns about DXM-containing products but does not specify avoidance by brand lines with those exact names.
Antidepressant risk with plain Mucinex is low/none.
Not stated in label; does not appear in Warnings/Drug Interactions as such.
Antidepressant risk with Mucinex DM is moderate (serotonin syndrome with SSRIs/SNRIs).
Not stated in label.
Antidepressant risk with Mucinex with pseudoephedrine is low, but monitor blood pressure.
Not stated in label.
SSRIs/SNRIs: DXM versions risky; plain Mucinex fine.
Not stated in label.
MAOIs (e.g., Nardil, Parnate): Highest risk—even plain Mucinex with pseudoephedrine can cause hypertensive crisis.
Label warns about MAOI interactions but does not specify 'highest risk' for plain Mucinex with pseudoephedrine.
TCAs (e.g., Elavil): Minimal issues with plain Mucinex.
Not stated in label.
Bupropion (Wellbutrin): Possible seizure risk with DXM, but rare.
Not stated in label.
FDA labels for Mucinex warn against use with MAOIs within 14 days.
This claim is marked as present; included in accurateStatements. It is not in unsupported Statements.
Pharmacists often recommend plain guaifenesin over combo products.
Not stated in label.
Always check your specific antidepressant via tools like Drugs.com interaction checker.
Not stated in label.
Prescription options like Tessalon (benzonatate) if needed.
Not stated in label.
Plain guaifenesin generics.
Not stated in label.
Honey or saline for mild symptoms.
Not stated in label.
Contradictions
Important Omissions
Precise dosing and administration details (e.g., 2 tablets every 12 hours; max 4 tablets per 24 hours; age 12+; under 12 not for use) as per Directions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Risk arises mainly from DXM interactions with antidepressants (notably MAOIs) and from pseudoephedrine-containing products; when used as plain guaifenesin, risk is low.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some antidepressant-interaction claims are not explicitly supported by the label; several statements extend beyond label content.
Suggested Improvement
Limit claims to label-supported interactions; clearly distinguish DXM-related interactions from general antidepressant considerations; incorporate exact dosing details from the Directions section.